2566 Stock Overview

Hangzhou Jiuyuan Gene Engineering Co., Ltd. More details

2566 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 86.7% below our estimate of its fair value

Earnings grew by 43.7% over the past year

Risk Analysis

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Hangzhou Jiuyuan Gene Engineering Co., Ltd. Competitors

JBM (Healthcare)

SEHK:2161

HK$1.5b

Dawnrays Pharmaceutical (Holdings)

SEHK:2348

HK$1.8b

Jacobson Pharma

SEHK:2633

HK$2.0b

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$863.6m

Price History & Performance

Summary of share price highs, lows and changes for Hangzhou Jiuyuan Gene Engineering
Historical stock prices
Current Share Price	HK$6.22
52 Week High	HK$9.10
52 Week Low	HK$6.17
Beta	0
1 Month Change	-22.06%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-18.69%

Recent updates

Shareholder Returns

	2566	HK Pharmaceuticals	HK Market
7D	-8.4%	-4.0%	-2.1%
1Y	n/a	-9.4%	16.9%

Return vs Industry: Insufficient data to determine how 2566 performed against the Hong Kong Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 2566 performed against the Hong Kong Market.

Price Volatility

Is 2566's price volatile compared to industry and market?
2566 volatility
2566 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	8.1%
10% most volatile stocks in HK Market	16.1%
10% least volatile stocks in HK Market	3.7%

Stable Share Price: 2566's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: Insufficient data to determine 2566's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	1,467	Hang Fu	www.china-gene.com

Hangzhou Jiuyuan Gene Engineering Co., Ltd. engages in the research, development, production and sales of biopharmaceutical products and medical devices. It offers Guyoudao, a recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair product; Jilifen, a Human granulocyte colony stimulating factor injection for neutropenia; and Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia.

Hangzhou Jiuyuan Gene Engineering Co., Ltd. Fundamentals Summary

How do Hangzhou Jiuyuan Gene Engineering's earnings and revenue compare to its market cap?
2566 fundamental statistics
Market cap	HK$1.53b
Earnings (TTM)	HK$136.88m
Revenue (TTM)	HK$1.41b

11.2x

P/E Ratio

1.1x

P/S Ratio

Is 2566 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2566 income statement (TTM)
Revenue	CN¥1.33b
Cost of Revenue	CN¥324.68m
Gross Profit	CN¥1.00b
Other Expenses	CN¥872.91m
Earnings	CN¥128.76m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.52
Gross Margin	75.52%
Net Profit Margin	9.71%
Debt/Equity Ratio	20.5%

How did 2566 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/03 17:57
End of Day Share Price	2025/01/03 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hangzhou Jiuyuan Gene Engineering Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Hangzhou Jiuyuan Gene Engineering SEHK:2566 Stock Report